Black Diamond Therapeutics, Inc. (BDTX): Shareholders' Equity
$112.21M
As of 2025-12-31
$96.09M
As of 2026-06-30
-1.0%
3-year compound annual growth
-18.3%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $112.21M | +34.7% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $83.28M | -28.7% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $116.74M | +0.9% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $115.69M | -40.9% | 2024-03-12, Balance as of period end |
| 2021-12-31 | $195.90M | -36.3% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $307.76M | n/m | 2022-03-17, Balance as of period end |
| 2019-12-31 | -$47.16M | n/m | 2021-03-25, Balance as of period end |
| 2018-12-31 | -$15.54M | n/a | 2020-03-24, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $112.21M | +34.7% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $765.28M | -33.5% |
| Compugen Ltd (CGEN) | 2025-12-31 | $102.73M | +87.1% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $1.13B | +9.3% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $178.13M | -58.3% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | -$5.79M | n/m |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $3.94M | +4.4% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $505.66M | -1.0% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $241.54M | +257.6% |
Compare BDTX, VIR, CGEN, RXRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗